Author response to "lack of benefit from low dose computed tomography in screening for lung cancer"
Open Access
- 26 August 2020
- journal article
- editorial
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 20 (1) , 1-3
Abstract
We explain to Dr. Benjamin (corresponding author) about why low-dose computed tomography reduce lung cancer mortality without significantly reducing all-cause mortality. We also conduct an up-to-date meta-analysis to evaluate low-dose computed tomography clinical effectiveness compared with usual care of lung cancer screening.Keywords
This publication has 7 references indexed in Scilit:
- Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized TrialNew England Journal of Medicine, 2020
- Lung Cancer Incidence and Mortality with Extended Follow-up in the National Lung Screening TrialJournal of Thoracic Oncology, 2019
- All‐cause mortality versus cancer‐specific mortality as outcome in cancer screening trials: A review and modeling studyCancer Medicine, 2019
- Effects of low-dose computed tomography on lung cancer screening: a systematic review, meta-analysis, and trial sequential analysisBMC Pulmonary Medicine, 2019
- Lung cancer mortality reduction by LDCT screening—Results from the randomized German LUSI trialInternational Journal of Cancer, 2019
- Why cancer screening has never been shown to “save lives”—and what we can do about itBMJ, 2016
- All-Cause Mortality in Randomized Trials of Cancer ScreeningJNCI: Journal of the National Cancer Institute, 2002